The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | Results of Phase Ib/II study of ricolinostat in multiple myeloma
Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA gives an overview of the Phase Ib/II study of ricolinostat (ACY-1215) in multiple myeloma (MM) (NCT01997840) presented at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. The trial looks at the combination of ricolinostat with pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma patients. Ricolinostat has a tendancy to be more selective for HDAC6 and according to Dr Raje, it is believed that it is has less off-target toxicity. Dr Raje further explains the rationale of combining with ricolinostat with lenalidomide and discusses data of the Phase Ib/II in 66 patients who have received up to six months of treatment. The data showed an overall response rate of approximately 46% with striking duration of response and progression-free survival (PFS) results. Dr Raje also discusses side effects observed in patients, which were managable.
